Updates in Heart Failure:

Slides:

Advertisements

Similar presentations

CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.

Advertisements

Purpose To determine whether metoprolol controlled/extended release

CHARM Program: 3 Component trials comparing candesartan with placebo.

Carvedilol Or Metoprolol European Trial Presented at European Heart Failure Meeting 2003 COMET Trial.

חזק בהגנה לבבית Valsartan in Heart Failure

SOLVD (Studies of Left Ventricular Dysfunction)

Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.

RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.

DIGOXIN USE AND TOXICITY TJ O’Neill 2/5/10. Historical Use of Digoxin  Romans used a non-Digoxin cardiac glycoside derived from sea onion  Used sporadically.

CC-1 Integrated Summary of V-HeFT and A-HeFT Trials Milton Packer, MD University of Texas Southwestern Medical Center at Dallas.

CIBIS II Cardiac Insufficiency Bisoprolol Study

Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.

CR-1 Candesartan in HF Benefit/Risk James B. Young, MD Cleveland Clinic Foundation.

Increased mortality among patients taking digoxin—analysis from the AFFIRM study or Lack of evidence of increased mortality among patients with atrial.

Plants Used to Treat Heart Disease and Circulatory Problems.

Digoxin Reduces 30-Day All-Cause Hospital

Upfront Combination Therapy vs Step-Up Approach for PAH:

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

CLINICAL DILEMMAS IN HEART FAILURE:

Emerging Concepts in Heart Failure

Acute Heart Failure.

دانشیار دانشکده دندانپزشکی دانشگاه علوم پزشکی شهید صدوقی یزد

Heart Failure and Hospital Readmissions

Heart Rate, HF Admissions, and Readmissions

A New Era for NOACs:.

Select Topics in Cardiovascular Medicine

New Perspectives in AF and PCI: Implications for the Practicing Physician.

Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.

Update on NSAID Use:.

It’s Elementary.

Cost Effectiveness and Optimal Outcomes in HF

Section III: Neurohormonal strategies in heart failure

Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.

Surveying the Safety of NOACs in the Real World

Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Heart Failure Prevention: Mission Impossible?

T2DM and CV Outcomes Trials: A Deep Dive!

Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS I)

ADA/EASD Position Statement: Approach to Hyperglycemia Management

Dispelling Myths and Misconceptions ACC/AHA 2013 Digoxin Guidelines for Heart Failure.

How to Optimize TAVR Outcomes

Tackling CV Risk in T2DM.

Expert Insights on Complex Clinical Cases of Edema

The Heart Failure Team Heart Failure Care Map First 24 hours.

Risk Stratification in CAD and PAD

Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?

CIBIS II: Cardiac Insufficiency Bisoprolol Study II

Using Heart Rate as a Biomarker in Clinical Practice.

Digoxin Reduces 30-Day All-Cause Hospital Admission in Ambulatory Older Patients with Chronic Heart Failure and Reduced Ejection Fraction ACC Late Breaking.

Case #1 Case #1 (cont) Case #1 (cont)

Revisiting the Pharmacoeconomics of HF

Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies

CAD and HF Often Coexist

New Strategies to Reduce HF Readmissions

Impedence-guided management

Iron Deficiency in Heart Failure

Section III: Neurohormonal strategies in heart failure

Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy.

Factor Xa Inhibitors in Coronary Artery Disease

Live on PAH: Breathing Life Into Patients With PAH

HF-Related Hospitalization and Readmissions

MOOD-HF Trial design: Patients with chronic systolic heart failure and comorbid depression were randomized to escitalopram (n = 185) vs. placebo (n = 187).

My PAH Patient.

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Key Data on Improving Outcomes in HF Patients

RAASi Enabling in the Modern Era

Rethinking Risk Stratification for Nonischemic HF:

Presentation transcript:

Updates in Heart Failure:

Foxglove

William Withering on Dose-Response of Digoxin

Learning Objectives

Unfortunately There is a Downside To Calcium Loading of Cells

PROVED/RADIANCE: No Added Benefit of High vs Low SDC on Worsening HF

Association of Serum Digoxin Concentration With Hospitalization Risk

DIG Trial: Significant Reduction in CHF Hospitalizations But No Effect on Mortality

Post Hoc DIG Trial SDC and Mortality

Survival Curves of Women Placebo vs High and Low Digoxin Serum Levels

Summary Clinical Points to Consider

Abbreviations

Abbreviations (cont)

References

References (cont)